MEDI 0700

Drug Profile

MEDI 0700

Alternative Names: AMG 570; Anti-B7RP-1mAb/BAFF; MEDI0700

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Bispecific antibodies; Peptides
  • Mechanism of Action B-cell activation factor receptor modulators; B7-related protein 1 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Aug 2017 Phase-I clinical trials in Rheumatoid arthritis in USA (SC) (NCT03156023)
  • 18 May 2017 Amgen plans a phase I trial for Rheumatoid arthritis (NCT03156023)
  • 01 Mar 2016 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in USA (SC) (NCT02618967)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top